FIRST AMENDMENT TO REVENUE INTEREST PURCHASE AND SALE AGREEMENTRevenue Interest Purchase and Sale Agreement • August 9th, 2024 • Roivant Sciences Ltd. • Pharmaceutical preparations • New York
This First Amendment to Revenue Interest Purchase and Sale Agreement (this “Amendment”) is made as of May 24, 2024, by and among DERMAVANT SCIENCES GMBH, a limited liability company organized under the laws of Switzerland (“Dermavant”), DERMAVANT SCIENCES, LTD., an exempted company organized under the laws of Bermuda, solely for purposes of Section 5.21 and Article VIII of the RIPSA (“Parent” and, together with Dermavant, the “Dermavant Parties”), XYQ LUXCO S.À R.L. (“XYQ Luxco”), NovaQuest Co-Investment Fund XVII, L.P. (“NovaQuest”), MAM Tapir Lender, LLC (“Marathon” and, with XYQ Luxco and NovaQuest, the “Purchasers”) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as collateral agent on behalf of the Purchasers (the “Collateral Agent”).
Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. Execution Version...Revenue Interest Purchase and Sale Agreement • August 8th, 2024 • Verona Pharma PLC • Pharmaceutical preparations • New York
